ArticleCell communication and signaling : CCS2025
Molecular and immune determinants of response in locally advanced deficient DNA mismatch repair/microsatellite instability-high gastric or gastroesophageal junction adenocarcinoma treated with neoadjuvant chemoimmunotherapy.
Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Engineered Phytoene-Producing Saccharomyces cerevisiae Alleviates Cyclophosphamide-Induced Intestinal Barrier Dysfunction and Gut Dysbiosis.Probiotics and antimicrobial proteins · 2026Article
- Mesothelial cell senescence induced by high glucose in peritoneal dialysis drives fibroblast activation and peritoneal fibrosis through KLF6-mediated activation of TGF-β pathway.Molecular and cellular biochemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundNeoadjuvant chemoimmunotherapy (NCIT) shows promise for resectable deficient DNA mismatch repair/microsatellite instability-high (dMMR/MSI-H) gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC). However, biomarkers associated with treatment response remain inadequately defined.
methodsWe analyzed 22 patients with resectable dMMR/MSI-H GAC/GEJAC treated with perioperative sintilimab plus oxaliplatin and S-1 (SOX). Clinical response, pathological regression, genomic alterations, and tumor microenvironment characteristics were assessed using imaging, histopathology, multi-omics, and multiplex immunohistochemistry.
resultsOf the 22 patients, radiological partial response was observed in 10, yielding an objective response rate of 45.5%. Seventeen patients underwent surgery, all achieving R0 resection. Becker tumor regression grades 1a, 1b, and 2 were observed in 10, 1, and 6 patients, respectively, corresponding to a pathological complete response rate of 58.8% (10/17). Two-year event-free and overall survival rates were 81.8% and 80.7%, respectively. Non-responders demonstrated worse survival and higher baseline intratumor heterogeneity, with enriched mutations in NF1, KDR, CDKN2A, and PLK1. Transcriptomic analysis revealed significant upregulation of GYLTL1B, PHLDA1, IGFN1, and SH2D5 in responders, along with activation of proliferative (E2F, MYC targets) and immune-stimulatory (TNFA via NFKB, IFN responses) pathways. Conversely, non-responders lacked these transcriptional signatures and displayed immunosuppressive features, including elevated methylated tumor-infiltrating lymphocytes (MeTIL) and T helper 17 (Th17) signature expression and increased infiltration of M1 macrophages. Post-treatment analysis showed favorable immune remodeling in responders, characterized by reduced M1 macrophages and increased dendritic and NK cell populations. Non-responders, however, exhibited minimal immune shifts but persistent M1 macrophage elevation. Certain biomarkers, including CDKN2A mutations, Fanconi anemia pathway alterations, and specific transcriptomic signatures, were found to correlate with both treatment response and prognosis.
conclusionsNCIT achieved high response rates and favorable survival outcomes in dMMR/MSI-H GAC/GEJAC. These findings underscore the potential of molecular-guided risk stratification to better predict treatment responses and personalized therapeutic strategies in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.